Literature DB >> 28590818

Work ability is influenced by kinesiophobia among patients with persistent pain.

Mona-Lisa Åkerström1, Anna Grimby-Ekman2, Mari Lundberg3.   

Abstract

The purpose of this study was to investigate how kinesiophobia fluctuates in patients over a four weeks multimodal rehabilitation program and to study the relationship between work ability and kinesiophobia. The study included 112 patients (94 women, 18 men). Measurements were made before, directly after, 2 months after, and 12 months after the program. The level of work ability was rated by the patients on a scale from 0% to 100%, and kinesiophobia was measured by the Swedish version of the Tampa Scale for Kinesiophobia (TSK-SV). Kinesiophobia decreased between the start of the multimodal rehabilitation program and the follow-up periods. Work ability increased over time, but not between baseline and the 2-month follow-up. Decreases in the TSK-SV score between baseline and the 2-month follow-up were related to the increased probability of improved work ability at the 12-month follow-up. In conclusion, a decrease in kinesiophobia seems to be related to increased work ability of patients participating in a 4-week multimodal rehabilitation program.

Entities:  

Keywords:  Chronic pain; fear of movement; physiotherapy; return to work; work capacity

Mesh:

Year:  2017        PMID: 28590818     DOI: 10.1080/09593985.2017.1328722

Source DB:  PubMed          Journal:  Physiother Theory Pract        ISSN: 0959-3985            Impact factor:   2.279


  1 in total

1.  Polish Adaptation of the Modified Tampa Scale of Kinesiophobia for Fatigue (TSK-F) and the Revision of the Tampa Scale in Terms of Pain for Cancer Patients.

Authors:  Mateusz Rozmiarek; Mateusz Grajek; Ewa Malchrowicz-Mośko; Karolina Sobczyk; Karolina Krupa-Kotara; Piotr Nowaczyk; Janusz Wasiewicz; Tomasz Urbaniak; Wojciech Siejak; Urszula Czerniak; Anna Demuth; Aitor Martínez Aguirre-Betolaza; Arkaitz Castañeda-Babarro
Journal:  Int J Environ Res Public Health       Date:  2022-10-05       Impact factor: 4.614

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.